A phase II, open-label study of ramucirumab (IMC-1121B), an IgG1 fully human monoclonal antibody (MAb) targeting VEGFR-2, in combination with paclitaxel and carboplatin as first-line therapy in patients (pts) with stage IIIb/IV non-small lung cancer (NSCLC)

被引：0
|
作者：
Camidge, D. R.
Ballas, M. S.
Dubey, S.
Haigentz, M.
Rosen, P. J.
Spicer, J. F.
West, H. J.
Shah, G. D.
Youssoufian, H.
Mita, A. C.
机构：
[1] Univ Colorado Denver, Aurora, CO USA
[2] NYU, Ctr Canc, New York, NY USA
[3] Univ Calif San Francisco, San Francisco, CA 94143 USA
[4] Montefiore Med Ctr, Bronx, NY 10467 USA
[5] Tower Canc Res Fdn, Beverly Hills, CA USA
[6] Guys Hosp, Div Canc Studies, Kings Coll London, London SE1 9RT, England
[7] Swedish Canc Inst, Seattle, WA USA
[8] ImClone Syst, New York, NY USA
[9] ImClone Syst, Branchburg, NJ USA
[10] Univ Texas Hlth Sci Ctr San Antonio, Inst Drug Dev, Canc Therapy & Res Ctr, San Antonio, TX 78229 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.7588
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7588
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC)
    Cohen, Roger B.
    Langer, Corey J.
    Simon, George Rajan
    Eisenberg, Peter David
    Hainsworth, John Daniel
    Madajewicz, Stefan
    Cosgriff, Thomas Michael
    Pierce, Kristen
    Xu, Huiping
    Liau, Katherine
    Healey, Diane
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2007, 60 (01) : 81 - 89
  • [32] Motesanib or bevacizumab in combination with paclitaxel and carboplatin in patients with advanced nonsquamous non-small cell lung cancer (NSCLC): interim results from a randomized, open-label, phase 2 study
    Blumenschein, G., Jr.
    Schwartzberg, L. S.
    Menon, H.
    Mok, T. S. K.
    Stephenson, J. J.
    Beck, J. T.
    Lakshmaiah, K.
    Kracht, K.
    Sikorski, R.
    Kabbinavar, F.
    EJC SUPPLEMENTS, 2009, 7 (02): : 555 - 555
  • [33] Open-label phase II study of S-1 as second-line therapy for patients with advanced non-small cell lung cancer (NSCLC)
    Govindan, R.
    Zergebel, C.
    Saito, K.
    Schiller, J. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [34] PHASE III, RANDOMISED, OPEN-LABEL, FIRST-LINE STUDY OF GEFITINIB (G) VS CARBOPLATIN/PACLITAXEL (C/P) IN CLINICALLY SELECTED PATIENTS (PTS) WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) (IPASS)
    Mok, Tony
    Wu, Yi-Long
    Thongprasert, Sumitra
    Yang, Chih-Hsin
    Chu, Datong
    Saijo, Nagahiro
    Jiang, Haiyi
    Watkins, Claire
    Armour, Alison
    Fukuoka, Masahiro
    ANNALS OF ONCOLOGY, 2008, 19 : 1 - 1
  • [35] A Phase 1b/2, Open-Label Study of Bintrafusp Alfa with Chemotherapy in Patients with Stage IV Non-Small Cell Lung Cancer
    Barlesi, F.
    Hiret, S.
    Rolfo, C.
    Grenga, I.
    Koenig, A.
    Vugmeyster, Y.
    Horn, L.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S27 - S27
  • [36] Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non-Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study
    Lynch, Thomas J.
    Bondarenko, Igor
    Luft, Alexander
    Serwatowski, Piotr
    Barlesi, Fabrice
    Chacko, Raju
    Sebastian, Martin
    Neal, Joel
    Lu, Haolan
    Cuillerot, Jean-Marie
    Reck, Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (17) : 2046 - 2054
  • [37] CP-751,871, an anti-IGF-IR antibody, in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC): A phase lb/randomized phase II, non-comparative, open label trial
    不详
    EJC SUPPLEMENTS, 2007, 5 (04): : 358 - 359
  • [38] AN OPEN-LABEL, MULTICENTER, RANDOMIZED, PHASE II STUDY OF CISPLATIN AND PEMETREXED WITH OR WITHOUT CIXUTUMUMAB (IMC-A12) AS FIRST-LINE THERAPY IN PATIENTS WITH ADVANCED NONSQUAMOUS NON-SMALL CELL LUNG CANCER
    Scagliotti, Giorgio
    Castro, Gilberto, Jr.
    Kiyik, Murat
    Ruben, Kowalyszyn
    Deppermann, Karl-Matthias
    Arriola, Edurne
    Bosquee, Lionel
    Willey, Richard G.
    Cosaert, Jan
    Reck, Martin
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S601 - S601
  • [39] A Phase II Study of S-1 and Paclitaxel Combination Therapy as a First-Line Treatment in Elderly Patients with Advanced Non-Small Cell Lung Cancer
    Yoshimura, Akihiro
    Chihara, Yusuke
    Date, Koji
    Tamiya, Nobuyo
    Takemura, Yoshizumi
    Imabayashi, Tatsuya
    Kaneko, Yoshiko
    Yamada, Tadaaki
    Ueda, Mikio
    Arimoto, Taichiro
    Uchino, Junji
    Iwasaki, Yoshinobu
    Takayama, Koichi
    ONCOLOGIST, 2019, 24 (04): : 459 - E131
  • [40] Phase 1-2a Multicenter Dose-Ranging Study of Canfosfamide in Combination with Carboplatin and Paclitaxel as First-Line Therapy for Patients with Advanced Non-small Cell Lung Cancer
    Sequist, Lecia V.
    Fidias, Panos M.
    Temel, Jennifer S.
    Kolevska, Tatjana
    Rabin, Michael S.
    Boccia, Ralph V.
    Burris, Howard A.
    Belt, Robert J.
    Huberman, Mark S.
    Melnyk, Ostap
    Mills, Glenn M.
    Englund, Craig W.
    Caldwell, David C.
    Keck, James G.
    Meng, Lisa
    Jones, Marsha
    Brown, Gail L.
    Edelman, Martin J.
    Lynch, Thomas J.
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (11) : 1389 - 1396
12345